Skip to main content
 

Profile

Glenn Cruse, PhD

Assistant Professor, Immunology

Contact:

gpcruse@ncsu.edu

Glenn Cruse completed his Ph.D. under the supervision of Professor Peter Bradding at Glenfield Hospital, The University of Leicester, UK in 2009. He then moved to the National Institutes of Health in Bethesda, Maryland in January 2010 to start a visiting postdoctoral fellowship in the Laboratory of Allergic Diseases, NIAID, under the supervision of Dr. Dean Metcalfe. In January 2015, Dr. Cruse was appointed as a Research Fellow in the same laboratory. Dr. Cruse joined the Department of Molecular Biomedical Sciences at NCSU in January 2016 as an Assistant Professor.

Dr. Cruse is a mast cell biologist that has authored and co-authored over 30 publications including articles in top journals such as the New England Journal of Medicine, Proceedings of the National Academy of Sciences USA and Immunity. The Cruse lab is interested in the role that mast cells play in allergic and inflammatory diseases and identifying novel therapeutics that target mast cells. Since mast cells act as sentinel cells that participate in both innate and acquired immunity, particularly at biological barriers, emphasis on diseases in tissues at the interface with the environment such as the lung, skin, gastrointestinal tract and even the neuro-immune axis are the main focus of the lab.
Affiliations
Member of the American Association of Immunologists
Member of the American Thoracic Society
Member of the American Academy of Asthma, Allergy & Immunology
Certifications
2009 Ph.D. University of Leicester Medical School, Leicester, UK
Immunology
The Cruse lab is interested in molecular immunology with particular focus on basic and translational research on allergy and inflammation. The mast cell is a critical regulator of allergic inflammation and thus a central focus of research in our lab. We have recently identified a method to specifically target mast cells by modifying gene splicing to eliminate expression of the high affinity IgE receptor on the mast cell surface, resulting in mast cells that are unresponsive to allergens. In addition to developing this therapeutic approach, our research goals include identifying other novel therapeutic targets and developing more effective treatments of allergic diseases, which have an unmet clinical need.

The key to achieving these goals is better understanding of the molecular mechanisms that trigger and promote allergic inflammation. Studies on mechanisms of activation and phosphorylation of different receptors in immune cells, and determining how they differ in signal transduction and protein trafficking pathways that regulate cytoskeletal reorganization and ionic conductance are of particular interest.

  • Exon skipping of FcεRIβ eliminates expression of the high affinity IgE receptor in mast cells with therapeutic potential for allergy.Cruse G*, Yin Y, Fukuyama T, Desai A, Arthur GK, Bäumer W, Beaven MA, and Metcalfe DD. | Proc Natl Acad Sci USA. In Press
  • (2016) Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis.Kirshenbaum AS, Cruse G, Desai A, Bandara G, Leerkes M, Lee CC, Fischer ER, O'Brien KJ, Gochuico BR, Stone K, Gahl WA, and Metcalfe DD. | PLoS One. 26;11(7):e0159177.
  • (2016) Vibratory Urticaria Associated with a Missense Variant in ADGRE2Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM, Eisch AR, Long RD, Lee CCR, Satorius CL, Pakstis AJ, Kidd KK, Kastner DL, Metcalfe DD, and Komarow HD. | N Engl J Med. Feb 3. [Epub ahead of print].
  • (2015) Flow cytometry-based monitoring of mast cell activationCruse G, Gilfillan AM, and Smrz D. | Methods Mol Biol. 1220:365-379.
  • (2015) The CD20-homologue MS4A4 directs trafficking of KIT toward clathrin-independent endocytosis pathways and thus regulates receptor signaling and recyclingCruse G, Beaven MA, Music S, Bradding P, Gilfillan AM, and Metcalfe DD. | Mol Biol Cell 26(9):1711-1727.
  • (2015) Mast cells in airway diseases and interstitial lung diseaseCruse G, and Bradding P. | Eur J Pharmacol. May 8. pii: S0014-2999(15)00408-2. doi: 10.1016/j.ejphar.2015.04.046.
  • (2014) Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasmsCruse G, Metcalfe DD, and Olivera A | Immunol Allergy Clin North Am. 34(2):219-237.
  • (2014) Rictor negatively regulates FcεRI-induced mast cell degranulationSmrz D, Cruse G, Beaven MA, Kirshenbaum A, Metcalfe DD, and Gilfillan AM. | J Immunol 193(12):5924-5932.
  • (2013) A truncated splice-variant of the FcεRIβ receptor subunit is critical for microtubule formation and degranulation in mast cellsCruse G, Beaven MA, Ashmole I, Bradding P, Gilfillan AM, and Metcalfe DD | Immunity 38(5):906-917.
  • (2013) Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulationSiegel AM, Stone KD, Cruse G, Lawrence MG, Olivera A, Jung MY, Barber JS, Freeman AF, Holland SM, O'Brien M, Jones N, Nelson CG, Wisch LB, Kong HH, Desai A, Farber O, Gilfillan AM, Rivera J, and Milner JD | J Allergy Clin Immunol 132(6):1388-1396.
  • (2012) Cold Urticaria, Immunodeficiency, and Autoimmunity Related to PLCG2 DeletionsOmbrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, Subramanian N, Bunney TD, Baxendale RW, Martins MS, Romberg N, Komarow H, Aksentijevich I, Kim HS, Ho J, Cruse G, Jung MY, Gilfillan AM, Metcalfe DD, Nelson C, O'Brien M, Wisch L, Stone K, Douek DC, Gandhi C, Wanderer AA, Lee H, Nelson SF, Shianna KV, Cirulli ET, Goldstein DB, Long EO, Moir S, Meffre E, Holland SM, Kastner DL, Katan M, Hoffman HM, and Milner JD | N Engl J Med 366(4):330-338.
  • (2011) Functional KCa3.1 K+ channels are required for human fibrocyte migrationCruse G, Singh S, Duffy SM, Doe C, Saunders R, Brightling CE and Bradding P | J Allergy Clin Immunol. 128(6):1303-1309.
  • (2010) Counterregulation of beta(2)-adrenoceptor function in human mast cells by stem cell factorCruse G, Yang W, Duffy SM, Chachi L, Leyland M, Amrani Y and Bradding P | J Allergy Clin Immunol 125(1):257-63.
  • (2010) Airway smooth muscle proliferation and survival is not modulated by mast cellsKaur D, Hollins F, Saunders R, Woodman L, Sutcliffe A, Cruse G, Bradding P and Brightling C | Clin Exp Allergy 40(2):279-88.
  • (2010) Activation of human mast cells through platelet activating factor receptorKajiwara N, Sasaki T, Bradding P, Cruse G, Sagara H, Ohmori K, Saito H, Ra C and Okayama Y | J Allergy Clin Immunol. 125(5):1137-1145.
  • (2010) Human lung mast cells mediate pneumococcal cell death in response to activation by pneumolysinCruse G, Fernandes VE, de Salort J, Pankhania D, Marinas MS, Brewin H, Andrew PW, Bradding P and Kadioglu A | J Immunol. 184(12):7108-7115.
  • (2010) A novel FcepsilonRI beta chain truncation regulates human mast cell proliferation and survivalCruse G, Kaur D, Leyland M and Bradding P | FASEB Journal 24(10):4047-4057.
  • (2009) Airway wall geometry in asthma and non-asthmatic eosinophilic bronchitisSiddiqui S, Gupta S, Cruse G, Haldar P, Entwisle J, McDonald S, Whithers PJ, Hainsworth SV, Coxson HO and Brightling CE | Allergy 64:951-958.
  • (2009) IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitisSiddiqui S, Cruse G, McKenna S, Monteiro W, Mistry V, Wardlaw A and Brightling C | BMC Pulm Med. 14;9:34.
  • (2008) Mast cells: Biological properties and role in health and allergic diseasesBradding P, and Cruse G, Barry Kay, Allen Kaplan, Jean Bousquet and Patrick Holt (Eds). Wiley-Blackwell | In Allergy and Allergic Diseases 2nd Edition pp. 217-257. ISBN: 978-1-4051-5720-9.
  • (2008) IgE alone promotes human lung mast cell survival through the autocrine production of IL-6Cruse G, Cockerill S, and Bradding P | BMC Immunology 9(2).
  • (2008) Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: co-operative roles for CADM1, stem cell factor and IL-6.Hollins F, Kaur D, Yang W, Cruse G, Saunders R, Sutcliffe A, Berger P, Ito A, Brightling CE, and Bradding P | J Immunol. 181(4):2772-80.
  • (2008) Engagement of the EP2 prostanoid receptor closes the K+ channel KCa3.1 in human lung mast cells and attenuates their migrationDuffy SM, Cruse G, Cockerill SL, Brightling CE, and Bradding P | Eur J Immunol. 38(9):2548-2556.
  • (2008) Mast cells promote airway smooth muscle cell differentiation via autocrine upregulation of TGF-beta 1Woodman L, Siddiqui S, Cruse G, Sutcliffe A, Saunders R, Kaur D, Bradding P and Brightling CE | J Immunol. 181(7):5001-5007.
  • (2007) Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration through the adenosine A2A receptorDuffy SM, Cruse G, Brightling CE, and Bradding P | Eur J Immunol. 37(6):1653-1662.
  • (2007) KCa3.1 Ca2+ Activated K+ Channels Regulate Human Airway Smooth Muscle ProliferationShepherd MC, Duffy SM, Harris T, Cruse G, Schuliga M, Brightling CE, Neylon CB, Bradding P, and Stewart AG | Am J Respir Cell Mol Biol. 37:525-531.
  • (2006) Functional KCa3.1 K+ channels are required for human lung mast cell migrationCruse G, Duffy SM, Brightling CE, and Bradding P | Thorax 61(10):880-885.
  • (2005) Beta2-adrenoceptor regulation of the K+ channel iKCa1 in human mast cellsDuffy SM, Cruse G, Lawley W, and Bradding P | FASEB Journal. 19:1006-1008.
  • (2005) Activation of human lung mast cells by monomeric immunoglobulin ECruse G, Kaur D, Yang W, Duffy SM, Brightling CE, and Bradding P | Eur Respir J. 25:858-863.
  • (2004) The K+ channel iKCa1 potentiates Ca2+ influx and degranulation in human lung mast cellsDuffy SM, Berger P, Cruse G, Yang W, Bolton SJ, and Bradding P | J Allergy Clin Immunol. 114:66-72.